Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 17/20 | 0.51 |
| ▸ | CHRM2 | P08172 | 16/20 | 0.51 |
| ▸ | ADRB2 | P07550 | 3/20 | 0.46 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.33 |
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.33 |
| ▸ | MGLL | Q99685 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2142412 | 0.96 | CHRM3 (0.45) | CHRM3CHRM2ADRB2ADRB1ADRA1D | |
| SCHEMBL2141435 | 0.95 | CHRM3 (0.51) | CHRM3CHRM2ADRB2ADRB1DRD2 | |
| SCHEMBL2140570 | 0.94 | CHRM3 (0.45) | CHRM3CHRM2ADRB2ADRB1DRD2 | |
| SCHEMBL2141465 | 0.91 | CHRM3 (0.42) | CHRM3CHRM2ADRB2 | |
| SCHEMBL2139233 | 0.91 | CHRM3 (0.45) | CHRM3CHRM2ADRB2ADRB1DRD2 | |
| SCHEMBL2140666 | 0.90 | CHRM3 (0.51) | CHRM3CHRM2ADRB2MGLL | |
| SCHEMBL2140962 | 0.90 | CHRM3 (0.43) | CHRM3CHRM2ADRB2 | |
| SCHEMBL2143064 | 0.89 | CHRM3 (0.52) | CHRM3CHRM2ADRB2ADRB1DRD2 | |
| SCHEMBL2141757 | 0.89 | CHRM3 (0.42) | CHRM3CHRM2ADRB2ADRB1DRD2 | |
| SCHEMBL2142256 | 0.89 | CHRM3 (0.52) | CHRM3CHRM2ADRB2ADRB1DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8629271-B2 | Compounds | ASTRAZENECA AB (GB) | 2014-01-14 | — | — | US | disclosed |
| US-20120322788-A1 | Compouds | PULMAGEN THERAPEUTICS (SYNERGY) LIMITED (GB) | 2012-12-20 | — | — | US | disclosed |
| EP-2242759-B1 | COMPOUNDS | ASTRAZENECA AB (SE) | 2012-09-12 | — | — | EP | disclosed |
| US-8148373-B2 | Compounds | ASTRAZENECA AB (SE) | 2012-04-03 | — | — | US | disclosed |
| US-20090298807-A1 | Compounds | ASTRAZENECA AB (SE) | 2009-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120322788-A1 | Compouds | PKD1, SBDS, ABCB11 | CHRM3 4265/4885CHRM2 3668/4885ADRB2 1366/4885 |
| US-20090298807-A1 | Compounds | PKD1, SLC10A1, ABCB11 | CHRM3 2714/4885CHRM2 2419/4885ADRB2 218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.